Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 14/20 | 0.52 |
| ▸ | SYK | P43405 | 3/20 | 0.48 |
| ▸ | YES1 | P07947 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | BRD2 | P25440 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.46 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30367804 | 0.94 | SRC (0.52) | SRCSYKYES1ABL1BCR | |
| SCHEMBL265051 | 0.94 | SRC (0.52) | SRCSYKYES1ABL1BCR | |
| SCHEMBL12320602 | 0.92 | SRC (0.54) | SRCABL1BCRJAK2BRD4 | |
| SCHEMBL12320601 | 0.91 | BRD4 (0.54) | SRCSYKYES1ABL1BCR | |
| SCHEMBL263862 | 0.86 | BRD4 (0.56) | SRCSYKYES1ABL1BCR | |
| SCHEMBL264711 | 0.85 | SRC (0.54) | SRCSYKYES1ABL1BCR | |
| SCHEMBL269990 | 0.80 | SYK (0.48) | SRCSYKYES1ABL1BCR | |
| SCHEMBL271265 | 0.78 | BRD4 (0.59) | SRCSYKYES1ABL1BCR | |
| SCHEMBL263867 | 0.77 | PRKCQ (0.51) | SRCSYKYES1JAK2BRD4 | |
| SCHEMBL12278053 | 0.74 | SYK (0.52) | SRCSYKYES1ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | SRC 80/4885SYK 281/4885YES1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.